



Personalized Neoantigen Peptide Vaccines

YGION Biomedicalは、術後のがん再発を予防するために、ネオアンチゲン・ペプチド・ワクチンを開発しています。

Company Overview

YGION Biomedical is a private preclinical stage biopharmaceutical company located in Vienna, Austria developing neoantigen peptide vaccines to prevent cancer recurrence post-surgery.

Lead program YG-01 is a fully individualized vaccine candidate that has completed preclinical development and will enter Phase 1 clinical testing in 2026, supported by 15MEUR Series A financing and 1MEUR grant funding raised. Follow on program YG-02 targets shared neoantigens and is in discovery.

YGION is led by a management team and advisory co-founder team with extensive biotech and Pharma experience across numerous companies.

Proprietary Technologies

YGNITE™ Neoantigen discovery pipeline combining next generation sequencing and in house bioinformatics (EP25169025, pending)

CARGONAUT™ Vaccine technology targets and activates antigen presenting cells for rapid and effective anti-tumor response against neoantigens (WO2014009209, Granted US, EP, AU, BR, CA, RU, JP; WO2017037158, Granted US, EP, JP, CN)

Lead Asset: YG-01

Patient specific neoantigen peptides identified from patient tumor samples, combined with YGION's proprietary CARGONAUT vaccine technology to trigger a superior anti-tumor immune response.

- Tumor reduction demonstrated in mouse tumor models
- GLP Toxicology and GMP manufacture completed
- Phase 1 clinical trial in Glioblastoma H1 2026

Seeking

- Co-Development Partners
- Licensing Partners
- Partners interested in R&D Collaborations around our platform technologies
- Investment: 10MEUR Series A2 sought